Respiratory syncytial virus (RSV-) vaccine
Abrysvo
Target group:
People aged 18 and over who want active protection against RSV disease of the lower respiratory tract.
In addition, Abrysvo is approved for use in pregnant women who are vaccinated between 24 and 36 weeks gestation. This provides passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth to 6 months of age.
Vaccination dose:
Single dose.
Protection duration:
It is not clear whether revaccination is needed.